drugset / Trial / NCT07240116

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

NCT07240116

Phase 1 Completed 18 enrolled Corcept Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

This single-center, randomized, open-label study will assess the relative bioavailability of 2 miricorilant (CORT118335) tablet formulations.

Timeline

Start
2025-09-11
Primary completion
2026-03-03
Completion
2026-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 100 mg Oral

Indications

No indication recorded.